BOTHELL, Wash., May 17 /PRNewswire/ — Microvision, Inc. (Nasdaq: MVIS) today reported that Dr. John Marshall, Frost professor of ophthalmology at
St Thomas’ Hospital in London, has joined Microvision’s recently established
Display Advisory Board.
A world leader in the study of laser use in ophthalmic diagnosis and
surgery, Marshall brings to the Microvision advisory board over 30 years of
experience in the study of the retina. In addition to serving as editor or
co-editor of a number of international journals, Marshall’s work has resulted
in over 300 research papers, book chapters and books. His research was
instrumental in the development of the Excimer laser for the correction of
refractive disorders and the world’s first diode laser for treating eye
problems of diabetes, glaucoma and ageing.
Marshall sits on many UK based and international committees focused on
safety standards for lasers and other artificial light sources. He currently
chairs the Medical Advisory Board and is a Trustee of the British Retinitis
Pigmentosa Society and until 1995 was co-chairman of the Medical and
Scientific Advisory Board of the International Retinitis Pigmentosa
Association. He is also a Fellow of the Royal Society of Arts, and an Honorary
Fellow of The College of Optometrists. Among his many honors, Marshall has
been awarded the Nettleship Medal of the Ophthalmological Society of the
United Kingdom, the Mackenzie Medal, the Raynor Medal, the Ridley Medal and
the Ashton Medal.
“I am delighted to join Microvision’s advisory board as the company has
developed a safe and exciting technology which has the clear potential to
revolutionize the way in which visual information is presented in work and
leisure environments,” said Marshall.
“Dr. Marshall is one of the world’s most renowned experts in the study of
laser and light to the retina,” noted Steve Willey, executive vice president
of Microvision. “The advisory boards’ goal is to help Microvision deliver the
best products possible, and Dr. Marshall’s input will prove invaluable in
ensuring the quality of Microvision’s products.”
The advisory group will consult with Microvision on future developments
and applications of its innovative retinal scanning display technology (RSD),
meeting several times a year with Microvision’s senior management and
engineering teams. Microvision plans to enlist some of the industry’s
brightest minds to help Microvision make the transition from technology
developer to manufacturer of commercial display and imaging products.
Headquartered in Bothell, Wash., Microvision, Inc. is the developer of the
patented retinal scanning display technology and a world leader in micro
miniature optical scanning technology for display and imaging applications.
The company’s technology has application in a broad range of military,
medical, industrial, professional and consumer information products.
Additional information can be found at the company’s Web site at
NOTE: Nomad and retinal scanning display are trademarks of Microvision, Inc.
The information set forth in this release includes “forward-looking
statements” within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended, and is subject to the safe harbor created by those
sections. Certain factors that realistically could cause results to differ
materially from those projected in the company’s forward-looking statements
are set forth in the company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as filed with the Securities and Exchange Commission.